APA-viite

Cheli, Y., Tulic, M. K., El Hachem, N., Nottet, N., Jacquel, A., Gesson, M., . . . Ballotti, R. (2021). ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer.

Chicago-tyylinen lähdeviittaus

Cheli, Yann, et al. "ITGBL1 Is a New Immunomodulator That Favors Development of Melanoma Tumors By Inhibiting Natural Killer Cells Cytotoxicity." Mol Cancer 2021.

MLA-viite

Cheli, Yann, et al. "ITGBL1 Is a New Immunomodulator That Favors Development of Melanoma Tumors By Inhibiting Natural Killer Cells Cytotoxicity." Mol Cancer 2021.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.